An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...

In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% reduction in LDL cholesterol at 12 weeks in patients with hypercholesterolemia ...

Thus, combining PCSK9 inhibitors with anti-PD-1/PD-L1 immunotherapy may be a new strategy to improve antitumor effects. Proprotein convertases (PCs) are a unique class of serine proteinases.

The candidate in question, dubbed AZD0780, is an oral small molecule PCSK9 inhibitor in development for dyslipidemia, a condition characterized by elevated cholesterol in the blood that can ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis—a primary driver of ...

A drug candidate, previously successful at treating severe fatty liver disease, reduces atherosclerosis — a primary driver of cardiovascular death ...

AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care lipid-lowering therapies such as statins. These new ...

Not everyone is sold on the benefits of early ezetimibe use, especially given the modest effect seen in IMPROVE-IT.

1,2 AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care-lipid lowering therapies such as statins.

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...